A Phase 2 interventional study of Candida antigen vaccine and Bivalent HPV vaccine in Warts and Human Papilloma Virus, sponsored by Zagazig University. Recruiting at 1 site in Egypt. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.
Sponsored by Zagazig University · Phase 2, Interventional, and Treatment
To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy
it is thought that candida antigen act through a cell-mediated immune response and bivalent HPV vaccine act mainly through humoral immunity, so we want to study their effect as single or mixed agents
171 studies on the registry are indexed under Warts; 35 are open to participants now.
This study's planned enrollment of 162 is above the median of 70 across 155 interventional studies indexed under Warts.
Browse Warts studies →Zagazig University is the lead sponsor of 459 studies on the registry; 77 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
54 patients will be treated with Candida antigen. All patients will be directly injected with Candida antigen into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
Biological: Candida antigen vaccine
54 patients will be treated with the Bivalent HPV vaccine. All patients will be directly injected with the vaccine into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
Biological: Bivalent HPV vaccine
54 patients will be treated with Both agents at the same session. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
Biological: Candida antigen vaccine · Biological: Bivalent HPV vaccine
we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
complete response
if there is disappearance of warts and return of the normal skin markings
Time frame: upto 3 months
partial response
if warts regressed in size by 50-99% (the size will be measured as the summation of size of all lesions in cm)
Time frame: upto 3 months
no response
if there is \< 50% decrease in wart size. (the size will be measured as the summation of size of all lesions in cm)
Time frame: upto 3 months
recurrence rate after recovery
appearance of new lesions or recurrence of previous one
Time frame: follow up for 6 months after recovery
Plan to share: No
Started Apr 2022 (actual). Primary completion is estimated for Oct 2025, 42 months after the start.
Of 18 phase 2 interventional studies under Warts, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's planned 42 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human papillomavirus vaccine, L1 type 16, 18